Matinas BioPharma CMO Departs, New Interim Appointed
Ticker: MTNB · Form: 8-K · Filed: Feb 7, 2025 · CIK: 1582554
| Field | Detail |
|---|---|
| Company | Matinas Biopharma Holdings, Inc. (MTNB) |
| Form Type | 8-K |
| Filed Date | Feb 7, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-change, personnel, compensation
TL;DR
Matinas BioPharma CMO out, interim in. Executive comp details also filed.
AI Summary
On February 5, 2025, Matinas BioPharma Holdings, Inc. reported the departure of Dr. Terry H. Liang from his role as Chief Medical Officer. The company also announced the appointment of Dr. Raphael J. N. Mannino as interim Chief Medical Officer. Additionally, the filing details compensatory arrangements for certain officers.
Why It Matters
Changes in key executive positions, especially the Chief Medical Officer, can signal shifts in strategic direction or operational focus for a pharmaceutical company.
Risk Assessment
Risk Level: medium — Executive departures and appointments can indicate internal changes that may affect the company's future performance and strategy.
Key Players & Entities
- Matinas BioPharma Holdings, Inc. (company) — Registrant
- Dr. Terry H. Liang (person) — Departing Chief Medical Officer
- Dr. Raphael J. N. Mannino (person) — Appointed interim Chief Medical Officer
FAQ
Who has departed from Matinas BioPharma Holdings, Inc.?
Dr. Terry H. Liang has departed from his role as Chief Medical Officer.
Who has been appointed as the interim Chief Medical Officer?
Dr. Raphael J. N. Mannino has been appointed as the interim Chief Medical Officer.
What is the date of the earliest event reported in this filing?
The earliest event reported is dated February 5, 2025.
What is the principal executive office address for Matinas BioPharma Holdings, Inc.?
The principal executive offices are located at 1545 Route 206 South, Suite 302, Bedminster, New Jersey 07921.
What other items are covered in this 8-K filing besides executive changes?
The filing also covers compensatory arrangements of certain officers and includes financial statements and exhibits.
Filing Stats: 864 words · 3 min read · ~3 pages · Grade level 9.9 · Accepted 2025-02-07 07:30:11
Filing Documents
- form8-k.htm (8-K) — 45KB
- ex99-1.htm (EX-99.1) — 10KB
- ex99-1_001.jpg (GRAPHIC) — 16KB
- 0001493152-25-005302.txt ( ) — 252KB
- mtnb-20250205.xsd (EX-101.SCH) — 3KB
- mtnb-20250205_lab.xml (EX-101.LAB) — 33KB
- mtnb-20250205_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MATINAS BIOPHARMA HOLDINGS, INC. Dated: February 7, 2025 By: /s/ Jerome D. Jabbour Name: Jerome D. Jabbour Title: Chief Executive Officer -3-